We are pleased to announce that Meddenovo Drug Design has completed the first closing of our pre-seed investment round, securing up to €1 million from ACT Venture Partners. This initial funding will accelerate the development of our AI-powered platforms for innovative therapeutic solutions. Co-founded by Dr. Ilke Ugur Marion and Dr. Antoine Marion, Meddenovo leverages advanced molecular modeling and the unique properties of cyclic peptides to revolutionize drug design. This investment will enhance our AI-driven capabilities, transition to a SaaS model, and expand our partnerships and customer base, positioning us to make a significant impact in the pharmaceutical industry by streamlining the development of effective therapies.